Introduction {#S1}
============

Since first described by Ashbaugh and colleagues in 1967 as "Adult Respiratory Distress Syndrome in Children," Pediatric Acute Respiratory Distress Syndrome (Pediatric ARDS) has been recognized as a distinct syndrome, with hallmarks and outcomes that differ from those of patients suffering from adult ARDS or neonatal RDS ([@B1]--[@B3]). Pediatric ARDS is a syndrome of non-cardiogenic pulmonary edema with clinical hallmarks including hypoxemia, bilateral radiographic opacities, increased venous admixture, decreased functional residual capacity, increased physiological deadspace, and decreased lung compliance. Early studies singled out lung surfactant deficiency that can be caused by a large variety of pulmonary and extra-pulmonary insults as an underlying factor in Pediatric ARDS, but the pathophysiology has since been recognized as much more complex ([@B3]). Key precipitating events are (1) activation of an unruly inflammatory milieu, which leads to (2) injury to the alveolar epithelial-endothelial permeability barrier, followed by (3) impaired alveolar fluid clearance. This fundamental change in pulmonary homeostasis can be caused by injury to either the alveolar or the capillary epithelium ([@B4]). The time course of lung structural damage in Pediatric ARDS has been classically thought to occur in three phases: an inflammatory exudative phase, characterized by diffuse alveolar injury with necrosis of alveolar type I cells, increase in vascular permeability, and an influx of inflammatory cells; a proliferative phase, starting approximately 72 h after the initial insult and lasting approximately 7 days, associated with alveolar epithelial type II (AEC2) repair; mesenchymal cell (interstitial fibroblast and myofibroblast) migration, proliferation, and secretion of extracellular matrix proteins, such as collagen; and a fibrotic phase, characterized by significant upregulation of collagen synthesis and chronic remodeling ([@B4]--[@B10]). Conventional treatments include ventilatory support, fluid clearance, and/or, in the most extreme cases, extra-corporeal membrane oxygenation (ECMO). Exogenous surfactant administration, prone positioning, and anti-inflammatory approaches, including administration of corticosteroids, may also be used, though consensus on the efficacy of these therapies is not universal, especially in children, for whom data are sparse ([@B3], [@B11]--[@B14]). Pediatric survivors with a history of ARDS exhibit pulmonary function characteristic of restrictive lung disease, though the severity of this functional deficit may fade over time, indicating a capacity for repair in a significant subset of patients. It has come to be understood that the timeline of disease progression in Pediatric ARDS is not as clearly as demarcated as originally described and outcomes can vary, dependent on both individual response and course of treatment. In this chapter, the complex cellular and molecular events that determine whether outcome features a more reparative or a more fibrotic profile will be examined. A better understanding of how fibrosis is precipitated and how repair might be facilitated in pediatric patients is critical for addressing the pulmonary fibrotic outcome of Pediatric ARDS, which is associated worldwide with significant levels of morbidity and mortality.

Pathophysiology and Outcomes: Pediatric ARDS Versus Adult ARDS and Neonatal RDS {#S2}
===============================================================================

Classically, Neonatal RDS has been described as a disease of lung immaturity with consequent surfactant insufficiency, which responds well to supplementary surfactant treatment. This approach has substantially changed outcomes for premature newborns and is one of the great success stories of modern neonatal medicine. In contrast, treatment of adult ARDS with supplementary surfactant has not been as successful ([@B15]--[@B18]). Studies by Willson and colleagues on pediatric patients show that children, while not as responsive as neonates, are still much more responsive to surfactant replacement therapy than adults. In a number of studies, Pediatric ARDS patients show improvement following administration of synthetic exogenous surfactants, particularly when the formula is stabilized ([@B19]--[@B22]). These differences in response are presumably due to the etiology of the syndrome in neonatal versus pediatric versus adult patients. In neonata patients suffering from prematurity, surfactant therapy not only supports pulmonary function but may also aid in lung maturation. In pediatric and adult lung, in which lungs have matured or are in the latter stages of maturing and which have no prior surfactant compromise, exogenous surfactant may acutely support lung function, but may not have as striking an impact on already mature epithelium. Although ARDS patients do suffer from diminished surfactant levels due to trauma to the surfactant secreting AEC2 population and/or sequestration of surfactant by substances present following edema or inflammation, the pathophysiology of the syndrome is clearly more complex than can be ascribed to this loss. Pediatric ARDS can occur in children with no pre-existing illnesses, but occurrence and mortality are both significantly higher in those with serious underlying conditions, including oncologic diagnoses and especially immune deficiency ([@B23]). The syndrome in children also differs from adult disease in outcome, again pointing to potential, underlying differences in pathophysiology. Overall mortality in Pediatric ARDS patients is much lower than that for adult patients. In fact, a subset of pediatric patients show a remarkable capacity for repair, whereas in Adult ARDS survivors, lung function is more often reduced long-term, with permanent alveolar simplification and fibrosis presumably due to regenerative failure. While pediatric survivors can be compromised by exertional dyspnea, hypoxemia, and, in some cases, persistent peripheral airway disease, these patients as a whole appear to possess a notable capacity to recover alveolar units destroyed by trauma ([@B24]--[@B26]).

Pediatric ARDS develops following a broad range of injuries, when breakdown of the alveolar permeability barrier leads to an influx of proteins and fluids across lung epithelium and endothelium and accumulation of protein-rich inflammatory fluid in the normally fluid-free alveolar space. Altered alveolar permeability and fluid accumulation occur in the setting of inflammation, featuring inappropriate activation of leukocytes and platelets, and uncontrolled activation of coagulation pathways. Solutes and large molecules, such as albumin, enter the alveolar space, creating a highly proteinaceous edema. Significant concentrations of cytokines \[e.g., interleukin (IL)-1, IL-8, and tumor necrosis factor (TNF)-α\] and lipid mediators (e.g., leukotriene B4) are also present. In response to pro-inflammatory mediators, leukocytes -- especially neutrophils -- migrate into the pulmonary interstitium and alveoli ([@B4]). The presence of protein, fibrinogen, and fibrin degradation products in the edema fluid due to impairment of alveolar fluid clearance leads to surfactant degradation and a subsequent increase in alveolar surface tension. A resulting fall in pulmonary compliance and increased alveolar instability ultimately lead to areas of atelectasis and significant pulmonary dysfunction.

Following acute lung injury (ALI), not only inflammatory cytokines but also growth-promoting agents, especially in pediatric patients that are still developing (e.g., PDGF, TGF-α, TGF-β), are released systemically and locally, as well as activated in the disrupted alveolar structure, which initiate repair processes in response to the injury. It appears that in a subset of pediatric patients, this response can occur swiftly in response to trauma. One retrospective study showed that Pediatric ARDS survivors that exhibit immediate, positive changes in response to treatment over the first 3 days following onset have much faster, more complete reparative outcomes compared to those who do not respond as quickly ([@B27]). How a slower response to treatment might contribute to fibrosis in survivors is still under investigation. Inappropriate mesenchymal cell proliferation and extracellular matrix production (known downstream responses to TGF-α and TGF-β, in particular) due to severe or repeated epithelial cell damage have been shown in both animal models and in human patients to eventually evolve into alveolar fibrosis ([@B28], [@B29]). As intra-alveolar fibrosis evolves, infiltrating leukocytes decrease and are replaced by increased numbers of mononuclear phagocytes within the alveolar wall and airspace. Additionally, a variety of signals that are capable of stimulating alveolar macrophage growth factor release (e.g., endotoxin, activated complement components) are present in the distal lung under most of the circumstances associated with acute pediatric lung injury. It may be that slower patient responses allow a cascade of signaling events to occur that promotes long-term, pro-fibrotic remodeling. Though this hypothesis has yet to be completely tested, multiple studies in animal models and on cadaveric human tissue have demonstrated potential mechanisms and intervention points for the development of fibrosis following ALI resulting in Pediatric ARDS.

This fibroproliferative response, which precludes alveolar repair, is regulated by many factors ([@B30], [@B31]). Madtes et al. described a role for the epithelial and mesenchymal cell mitogen transforming growth factor (TGF)-α in the fibroproliferative response in ARDS and have shown that significant levels of TGF-α and procollagen peptide (PCP) III, a biological marker of fibroproliferation, are present in the BAL fluid of ARDS patients. Armstrong et al. noted that BAL fluid from patients with ARDS showed an early shift in the balance between type I collagen synthesis and degradation by collagenase, which favors development of fibrosis ([@B32]). As early as 36 h following the onset of injury, this fibrotic phase begins with extensive remodeling of sparsely cellular and collagenous tissue within the distal lung ([@B30]). Early morphologic examination of the lungs of patients that die from ALI reveals a common anatomic theme, in which a marked accumulation of mesenchymal cells and their connective tissue products appear in the alveolar airspace and in the walls of intra-acinal microvessels, i.e., an acute fibroproliferative response ([@B33]). On gross examination, the lungs of patients with ARDS appear heavy and edematous. The surface appears violaceous and hemorrhagic fluid exudes from the cut pleural surface ([@B4]). Microscopically, within hours of the onset of lung injury, the air-lung interface is denuded as type 1 epithelial cells (AEC1) die; within a few days after the inciting injury, there are intra-alveolar accumulations of mesenchymal cells, macrophages, and inflammatory cells ([@B33]--[@B35]). The interstitium becomes expanded with an increasing number of mesenchymal cells and numerous collagen fibrils and elastic fibers ([@B35]). The epithelial basement membrane becomes compromised with gaps of denuded areas, leaving the disrupted interstitium in direct communication with the alveolar airspace. Hyaline membranes form in the absence of alveolar epithelium. Vascular obliteration by microthrombi and fibrocellular proliferation also occurs. Activated myofibroblasts from the interstitium migrate into the alveolar airspace through the gaps in the compromised basement membrane and attach to the luminal surface of the damaged basement membrane ([@B36]). While presumably an attempt at repair, blockage of further damage, and/or a valiant effort to prevent drowning due to vascular leak, once myofibroblasts proliferate and persist, the excessive production of abnormal extracellular matrices ultimately obliterates the gas exchange unit. Immunohistochemical studies have shown increased amounts of fibronectin in the airspaces of ARDS patients. Biochemical analysis has also shown an accumulation of collagens type I and III in the expanded interstitium, with type III collagen predominantly present in the early stages following lung injury and type I collagen present at a later stage ([@B36], [@B37]).

Thus, the fibrotic phase of Pediatric ARDS is identified by the deposition of excess collagen and other extracellular matrix material and is associated with intra-alveolar, alveolar septal wall and alveolar ductal fibrosis as there is an attempt by the body to recreate the alveolar basement membrane that overlies collapsed and atelectatic regions of the lung ([@B30], [@B38]). Together, these pathologic changes result in the impaired lung physiology characteristic of Pediatric ARDS, which includes decreased functional residual capacity, diminished compliance accompanied by an increase in the work of breathing, increased deadspace and shunt fraction, and impaired gas exchange ([@B39]--[@B41]). The persistence of fibrosis in adult ARDS survivors has been documented to 2 years or more, by biopsy ([@B25]). Data on pediatric ARDS survivors show much more potential for repair, though this has mainly been demonstrated indirectly, by follow up that includes spirometry. Conversely, pediatric patients that respond poorly to initial treatments, even if they do not succumb, exhibit a problematic course of recovery that may require prolonged ventilation that can last much longer than that administered to quickly responding pediatric patients and adult survivors ([@B23], [@B42]). Unfortunately, this mechanical intervention has a well-known capacity to feed forward to create further injury via mechanical stretch and mesenchymal activation, thereby exacerbating the development of fibrosis.

Mechanical Ventilator Associated Fibrosis {#S3}
=========================================

It is important to consider the role of mechanical ventilation in the development of fibrosis in Pediatric ARDS patients. Protective mechanical ventilation is considered the most important supportive therapy for pediatric patients with ARDS. This approach was first validated by a multicenter randomized trial on Adult ARDS patients conducted by the ARDS Network under the auspices of the National Institutes of Health ([@B43]). Subsequent trials for Pediatric ARDS patients have generated some equivocal data, but the general agreement in the field is that ventilator support, including high-frequency oscillating ventilation (HFOV), especially if applied early in the disease course, has a beneficial impact ([@B11], [@B12], [@B42]). However, mechanical ventilation can also induce or aggravate lung injury, referred to as ventilator-induced lung injury (VILI) ([@B5]), to which the smaller, still maturing lungs of children can be particularly susceptible. The level of antioxidants, a critical component of lung homeostasis, can be compromised in Pediatric ARDS by alterations in both cell populations and the balance of proteins and water in interstitial spaces, leading to increased susceptibility to oxygen toxicity induced by forced ventilation. Pro-inflammatory and profibrotic responses may become persistent or uncontrolled during mechanical ventilation. Notably, recent ventilation strategies aimed at decreasing lung stretch has significantly decreased mortality ([@B11], [@B12]). However, the morbidity of mechanical ventilation remains as ventilation at high transpulmonary pressures leads to "barotrauma" and alveolar overdistention leads to "volutrauma," both characterized by increased alveolar-capillary leak and pulmonary edema ([@B44], [@B45]). Repeated opening and collapsing of delicate alveolar spaces at abnormally high pressures contributes to injury via a mechanism called "atelectrauma" ([@B46]). In all, there is an emerging evidence demonstrating that barotrauma, volutrauma, and/or atelectrauma from mechanical ventilation influence the course of lung remodeling in experimental models, which provide insight into the pathologies observed in over-ventilated Pediatric ARDS patients ([@B47], [@B48]).

In isolated rat lung and in lung parenchymal strips, mechanical stretch results in enhanced PCPIII expression. Application of recruitment maneuvers associated with atelectasis has also been shown to increase PCPIII expression in animal models of ARDS. In open-chest rabbits, mechanical ventilation with a high-positive end expiratory pressure led to greater gene expression of PCPIII, procollagen IV, fibronectin, and TGF-β1, the classical growth factor for fibrosis formation ([@B49]--[@B51]). In contrast, ventilation with a low PEEP did not stimulate expression of these genes. Furthermore, mechanical ventilation causes injury not only by structural disruption of the lung but also by induction of inflammatory responses associated with mediator release, which can worsen lung injury and potentially cause systemic organ dysfunction ([@B52]--[@B55]). The physical forces generated during mechanical ventilation can induce the release and/or activation of cytokines, chemokines, and growth factors in lungs, which together with inflammatory cell recruitment, may play a significant role in the progression from injury to fibroproliferation in pediatric patients. This altered condition in the lung presumably impacts any ability to repair. It can also alter the homeostatic profile and function of the lung even after repair, making once-damaged lungs especially vulnerable to further injury. Taken together, these studies suggest that atelectasis and alveolar overdistention due to mechanical ventilation are harmful and can lead to or exacerbate the development of fibrosis, while careful ventilation management in responsive patients, can support repair.

Repair {#S4}
======

Pediatric lungs in general have a substantial potential for repair and recovery after ARDS. In major treatment centers, a majority of pediatric patients recover from ARDS. In community treatment settings, as well as globally, this percentage is lower, however, indicating that a critical, early time frame exists for effective intervention. This hypothesis is reinforced by the observation that pediatric patients that respond rapidly to treatment and/or recover by 6 months following the initial insult often recover completely ([@B23]). However, pediatric lung injury can have divergent outcomes, with the appearance of fibrosing alveolitis in some patients versus others with seemingly equivalent degrees of lung injury that resolve the inflammation without evidence of fibrosis. The underlying molecular basis of these different outcomes is unclear. Tissue repair involves a variety of mechanisms including edema reabsorption, resolution of inflammation, and cell proliferation in order to repopulate the alveolar epithelium. Strategies that support these natural mechanisms of repair are currently under study using both animal models and clinical trials (Table [1](#T1){ref-type="table"}). Unfortunately, few of these present data on long-term outcomes for Pediatric ARDS patients. Thus, a better understanding of the mechanisms underlying repair in the juvenile lung, and how they may be supported by conventional and experimental therapies, is highly warranted.

###### 

**Pediatric ARDS Therapies (NB: impact on repair versus fibrosis as a long-term outcome is currently unknown, even for animal studies, for all treatments)**.

  Therapy                                                                                                Data from animal models (adult or neonatal)           Data from *pediatric* pilot and experimental studies and clinical trials    In use routinely or experimentally in *pediatric* patients
  ------------------------------------------------------------------------------------------------------ ----------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Ventilatory support                                                                                    ([@B56]--[@B58])                                      ([@B3], [@B11], [@B12], [@B43], [@B59]--[@B61])                             Yes[^b^](#tfn2){ref-type="table-fn"}
  Fluid clearance                                                                                        ([@B62])                                              ([@B59], [@B63]--[@B65])                                                    Yes^[a](#tfn1){ref-type="table-fn"},[b](#tfn2){ref-type="table-fn"}^
  ECMO                                                                                                   ([@B66])                                              ([@B67], [@B68])                                                            Yes[^b^](#tfn2){ref-type="table-fn"}
  Surfactant replacement therapy using synthetic and animal-derived surfactants, ±inhaled nitric oxide   ([@B57], [@B69]--[@B77]), reviewed in Ref. ([@B16])   ([@B19]--[@B21], [@B78]--[@B92]) reviewed in Ref. ([@B16], [@B22])          Yes^[a](#tfn1){ref-type="table-fn"},[c](#tfn3){ref-type="table-fn"},[d](#tfn4){ref-type="table-fn"}^
  Corticosteroids and other anti-inflammatories and fluid clearance agents                               ([@B93]--[@B95])                                      ([@B96])^[e](#tfn5){ref-type="table-fn"},[f](#tfn6){ref-type="table-fn"}^   Yes^[a](#tfn1){ref-type="table-fn"},[c](#tfn3){ref-type="table-fn"}^
  Gene therapy for fluid clearance and anti-inflammatory impact                                          ([@B97]--[@B105]), reviewed in Ref. ([@B106])         ND[^e^](#tfn5){ref-type="table-fn"}                                         No
  Mesenchymal (or other) stem cells                                                                      Reviewed in Ref. ([@B107])                            ND[^e^](#tfn5){ref-type="table-fn"}                                         No
  Growth factors (epidermal and fibroblast growth factor family members)                                 ([@B108]--[@B113])                                    ND                                                                          No

*^a^Used in conjunction with ventilatory support*.

*^b^Recommended by the Pediatric Acute Lung Injury Consensus Conference Group*.

*^c^Not recommended by the Pediatric Acute Lung Injury Consensus Conference Group but may be considered in severe cases*.

*^d^Clinical trials have curtailed use of certain synthetic surfactants that have shown lesser efficacy than animal-derived surfactants*.

*^e^Trials, safety, pilot, or experimental studies performed in adult patients; few or no studies in pediatric patients*.

*^f^Trials, safety, pilot, or experimental studies performed in neonatal or premature patients; few or no studies in pediatric patients*.

The inflammatory response in ARDS is a complex sequence of events that requires the interplay between several immune mediators ([@B114], [@B115]). In the most reparative scenario, anti-inflammatory cytokines (e.g., IL-10) are released as a negative feedback mechanism. When pro-inflammatory pathways are downregulated, these anti-inflammatory mediators can then decrease cytokine expression. Although anti-inflammatory mediators are involved in limiting inflammation, there are also pro-resolution mediators that act to mitigate inflammation and restore tissue homeostasis without causing immune suppression. Pro-resolution mediators include several classes of signaling molecules generated from polyunsaturated fatty acids: lipoxins, resolvins, and protectins ([@B4]). These agents appear to signal the recruitment of macrophages, the phagocytosis of apoptoic neutrophils, and the secretion of molecules that can act as anti-inflammatory agents at later stages of recovery, such as IL-10 and TGF-β. Apoptosis of inflammatory cells, mainly neutrophils, has also been shown when pro-survival signals such as granulocyte-colony stimulating factor (G-CSF), disappear. Alveolar macrophages have also been shown to play a role in this phase by engulfing apoptotic cells ([@B114]). Therefore, modulation of the inflammatory milieu using corticosteroids, direct administration of anti-inflammatory cytokines, or administration of recombinant viruses or modified stem cells that secrete immunomodulatory molecules have all been proposed to address this aspect of Pediatric ARDS. As yet, with the exception of steroid administration, these approaches have yet to move beyond the experimental phase.

The regeneration of the alveolar structure requires the proliferation and differentiation of AEC2 progenitors into AEC1 pneumocytes ([@B116]). It was recently established that the oxygen environment has a significant impact on AEC2 stem cell capacity during development, which may also occur following injury ([@B117]). This may particularly hold true in the case of Pediatric ARDS, where oxygenation is disrupted by trauma and artificially modulated by ventilation. Repair of the epithelium is a complex process that involves epithelial cell spreading and migration, as well as proliferation and differentiation of the stem cell population. It is this critical response that may underlie the difference between Pediatric and Adult ARDS patients in their capacity for both initial recovery and long-term return to normal lung function. Given the more robust nature of chronologically younger stem cells, therapeutic approaches that support stem cell function should be a priority for pediatric patients as newer treatments are developed. During the early stages of epithelial repair, epithelial progenitor cells migrate along the underlying matrix that is, in turn, remodeled during the repair process. Growth factors (EGF, KGF, and HGF) that act through tyrosine-kinase receptors, promote cell proliferation ([@B116]), and exogenous administration of KGF *in vivo* has been shown to speed this process \[([@B118]--[@B120]), reviewed in Ref. ([@B121])\]. Multiple other molecules that support lung progenitor cells have been extensively studied, *ex vivo*, in isolated primary human and animal cells in culture and in non-transformed human lung cell lines. These include chemokine receptors, anti-inflammatory ILs, eicosinoids, modulators of integrins, and matrix metalloproteinases (MMPs) to aid spreading and wound closure while blocking excessive collagen deposition, modulation of Rho GTPases and MAP kinases, modulation of STAT, PTEN, and PI3 kinase signaling, all critical for a broad range of stem cell functions, modulators of epithelial-mesenchymal transition, including Wnt1, TGF-ß, and E-cadherin ([@B121]). As yet, few of these attempts to modify and/or support epithelial stem cell-directed repair have been translated to even comprehensive *in vivo* studies, and clinical trials have yet to be achieved. Likewise, use of gene therapy or modified stem cell therapy approaches that modulate the function of these molecules and pathways within the context of Pediatric ARDS are still highly speculative approaches, with limited data available from laboratory studies and contraindications from experimental adult human trials ([@B106]). Additional studies have attempted to determine the regenerative capacity of subsets of endogenous progenitor cells in the absence of exogenous support, though these studies too are at a very early stage and recapitulation using human lung stem cell and progenitor populations has been slow. Endogenous progenitor cells include both resident epithelial and mesenchymal stem cells and bone marrow-derived mesenchymal cells. Recent studies in rodent models suggest that there may be other lung progenitor cells involved in the repair of the lung epithelium, including club cells, integrin α6β4 alveolar epithelial cells, and Scgb1a1-expressing cells and AEC1 themselves ([@B122]--[@B124]). However, the majority of data to date on lung epithelial response to injury has been generated by focusing on the role of AEC2. AEC2 classically represent the resident stem cells that can proliferate after injury and transdifferentiate into AEC1. In experimental models, AEC2 have been shown to migrate, proliferate, and differentiate into AEC1 ([@B125]). A recently developed experimental mouse model of extreme (\>80%) AEC2 depletion that results, at both acute and long-term follow up stages, in a distal lung that phenotypically resembles that of ARDS patients that suffer fibrotic outcomes, indicating the essential role for these cells in alveolar homeostasis ([@B126]). Furthermore, newer data show that if this depletion is induced in juvenile mice, repair is more robust and outcome is much more favorable. These data indicate that resident distal lung stem cell populations harbor highly functional stem cells capable of efficient repair under favorable circumstances.

In addition to its stem cell capacity, the AEC2 population also plays a critical role in surfactant production. Though surfactant therapy is often considered an acute response to the problem of surfactant deficiency that occurs within the early stages of ARDS, there are experimental data to show that the presence of surfactant itself is critical for maintaining AEC2 homeostasis ([@B127]--[@B129]). Additional data from animal models and studies using isolated patient cells indicate that a robust, functional AEC2 population and the presence of normal surfactant levels function as a defense against development of fibrosis ([@B130]--[@B133]). Thus, surfactant therapy for Pediatric ARDS, while it has still not achieved the level of success when used for Neonatal RDS, is still considered a promising and important mechanism for supporting repair ([@B16], [@B22]), particularly when used in conjunction with standard ventilation approaches. This is especially true for ARDS caused by direct pulmonary insults (infection, trauma, radiation, drowning, toxin exposure), where the pulmonary epithelium, including AEC2 is the main target, versus indirect causes (sepsis, burns, shock, transfusions), where damage to the alveolar capillary epithelium may play a greater role. Thus, this latter variety of Pediatric ARDS may not be as responsive to alveolar epithelial supportive therapy ([@B21], [@B78]).

Interestingly, there is also evidence that populations of pulmonary and even extra-pulmonary-derived stem cells that are present in the circulation in response to ARDS may play a role in alveolar regeneration. Lung mesenchymal cells are activated after lung injury and, in addition to collagen synthesis, may secrete growth factors and modulate the immune system by secreting anti-inflammatory cytokines ([@B134]). Clinical observations indicate the presence of endothelial progenitor cells post-ALI that may contribute to repair, though findings so far have been limited to adult and neonatal patients and to animal models ([@B107]). In contrast, a study by Bui and colleagues pediatric patients being treated by ECMO, including some suffering from Pediatric ARDS, showed that distinctive populations of stem-like cells of hematopoietic, mesenchymal, and epithelial lineages could be isolated from ECMO circuits, indicating that novel stem-like cell populations may be mobilized into the circulation by severe lung injury ([@B135]). Interestingly, the lineage prevalence and stem-like characteristics of these cells differed with patient age, again supporting the observation that pediatric ARDS patients respond in ways unique to their chronological age, in ways that differ from Neonatal RDS and Adult ARDS patients. An additional finding from this study was that a significant number of stem-like cells, especially those exhibiting characteristics of epithelial progenitors, were isolated from ECMO circuits very early in course of treatment, which correlates with the observation that those patients that respond quickly to treatment exhibit better outcomes. Taken together, these data indicate that early interventions that support endogenous stem cell function and take advantage of the patients' own response to pulmonary insult should be a focus of future treatments. In addition, conventional treatments that support reparative outcomes should also be more thoroughly investigated and augmented where possible.

One conventional treatment that impacts surfactant function, as well as the general integrity of the alveolar space, is fluid reduction. In order to restore normal respiratory function post-injury, collagen scars formed to preserve alveolar integrity and prevent drowning due to edema caused by vascular leak. These scars must be processed and removed by MMPs, a family of enzymes that digest extracellular fibers ([@B136]). One of the most important sources of MMPs is inflammatory cells, such as neutrophils and macrophages. Thus, ironically, the inflammatory response that can cause acute injury is important during resolution stages for adequate lung repair. MMPs represent one of the links between these two phenomena of inflammation and repair. MMPs are upregulated during the repair process and appear to be involved in facilitating cellular migration and the remodeling of the ECM ([@B121]). Studies in animal and tissue culture models indicate that migration and proliferation of epithelial progenitor cells are regulated by soluble factors released in response to lung injury. These factors include members of the epidermal growth factor family (EGF and TGF-α) and fibroblast growth factor family (HGF, KGF, FGF-10). Once the alveolar permeability barrier is re-established, removal of lung edema occurs via movement of water out of the airspaces through aquaporins (water channels) in AEC2, which is driven by the active transport of sodium and chloride through specific epithelial cell ion channels (eNAC and CFTR) ([@B101], [@B106], [@B137]--[@B140]). This endogenous repair function can be augmented by mechanical suction, with or without saline lavage ([@B140], [@B141]). More recent studies have focused on pharmacological stimulation of epithelial ion channels, though these studies, again, are still at the experimental stage.

Summary {#S5}
=======

Since identification of the pathways involved in lung injury, most of the literature has been focused on the use of therapies aimed at truncating the inflammatory response. However, recent studies have, and future studies should, focus on enhancing the repair process. Using approaches that address both acute inflammation and support repair in combination has also been given recent consideration, as each may address particular pathways that contribute to shifting long-term outcomes from pro-fibrotic to pro-repair ([@B16], [@B142], [@B143]). While Pediatric ARDS survivors exhibit an obstructive disease phenotype, at least during the acute phase and within the first year following recovery, significant long-term improvement in some patients has been documented. It is therefore imperative to consider bold strategies that could support repair during this period. A variety of approaches have been suggested, ranging from the use of biocompatible materials or cells to bolster remodeling to the therapeutic use of mediators aimed at promoting normal cell proliferation, migration, and differentiation. Because the mechanisms that cause tissue disruption and inflammation in the early phase of lung injury also contribute to repair and matrix remodeling later on, a fundamental key to future therapy is impeding the onset of fibrosis. Thus, therapies that disrupt pro-inflammatory pathways, such as MMP inhibition, may have a prophylactic value. Growth factors, exogenous stem cells, or drugs that promote matrix remodeling could also improve both the short- and long-term prognosis of patients with ARDS. Knowledge of the mediators involved in tissue repair and re-establishment of normal development and lung homeostasis could lead to new therapeutic strategies being applied of pediatric patients after the initial insult has been controlled. In fact, given the much higher potential for regeneration and repair in children, future experimental and clinical studies should be directed toward therapies for these patients that support effective repair, proper regeneration, and a return to homeostasis.
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